Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Total Assets · Q4 FY2025 · quarter ended Dec 2025
Total assets rises 59.8% from a year ago
Total assets stood at $30.24M at the end of Q4 FY2025, up 59.8% from a year earlier. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +59.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 30.24M USD
- Year-over-year change
- +59.8%
- 4-year CAGR
- +57.5%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.24M | +59.8% |
| FY2024 | 2024-12-31 | 18.92M | +19.7% |
| FY2023 | 2023-12-31 | 15.81M | +13.3% |
| FY2022 | 2022-12-31 | 13.96M | +184.0% |
| FY2021 | 2021-12-31 | 4.92M | — |
Total Assets vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +59.8% is the 4th highest of 10, against a peer median of +0.1%.
- Over three fiscal years its annual growth of +29.4% compares with a peer median of -4.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $13.18B USD | -5.1% | -3.4% | |
| Mar 2026 | CA$1.31B CAD | +0.1% | -5.0% | |
| Mar 2026 | $1.05B USD | -5.2% | -15.6% | |
| Mar 2026 | $531.74M USD | +66.6% | +2.2% | |
| Mar 2026 | $504.61M USD | +186.8% | +56.4% | |
| Dec 2025 | $335.38M USD | — | — | |
| Feb 2026 | $260.68M USD | -8.7% | -20.3% | |
| Mar 2026 | $136.19M USD | +1.5% | -4.8% | |
| Mar 2026 | $128.9M USD | -54.1% | -14.2% | |
| Mar 2026 | $93.42M USD | +210.7% | +20.8% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $30.24M USD | +59.8% | +29.4% |
| Peer median (excluding NNNN) | — | +0.1% | -4.8% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.